These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 20190286)
1. Serotonin 5-HT3 receptor antagonist for treatment of severe diabetic diarrhea. Murao S; Hosokawa H Diabetes Care; 2010 Mar; 33(3):e38. PubMed ID: 20190286 [No Abstract] [Full Text] [Related]
2. Ramosetron might be useful for treating diabetic diarrhea with a rapid small bowel transit time. Lee TH; Lee JS Korean J Intern Med; 2013 Jan; 28(1):106-7. PubMed ID: 23346005 [No Abstract] [Full Text] [Related]
3. Effect of the 5-hydroxytryptamine3 (5-HT3)-receptor antagonist KB-R6933 on experimental diarrhea models. Ozaki A; Yoshidomi M; Sukamoto T Jpn J Pharmacol; 1999 May; 80(1):93-6. PubMed ID: 10446763 [TBL] [Abstract][Full Text] [Related]
4. [Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea]. Hirata T; Funatsu T; Keto Y; Akuzawa S; Akiho H; Nishida A; Sasamata M; Miyata K Nihon Yakurigaku Zasshi; 2009 May; 133(5):281-91. PubMed ID: 19443966 [No Abstract] [Full Text] [Related]
5. Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents. Hirata T; Funatsu T; Keto Y; Akuzawa S; Sasamata M; Miyata K J Pharmacol Sci; 2008 Feb; 106(2):264-70. PubMed ID: 18296863 [TBL] [Abstract][Full Text] [Related]
8. [The clinical and experimental evaluation of the pharmacological efficacy of the new antidiarrheal preparation ftorazol]. Namitokov KhA; Pak SG; Astashkin EI; Grachev SV; Malova VA Ter Arkh; 1997; 69(11):18-21. PubMed ID: 9483738 [TBL] [Abstract][Full Text] [Related]
9. 5-HT3 receptor antagonists: new promising therapeutic agents in diabetes and its complications. Rahimian R; Ejtemaei Mehr S; Fakhfouri G; Dehpour AR Acta Med Iran; 2013; 51(10):736. PubMed ID: 24338152 [No Abstract] [Full Text] [Related]
11. The involvement of 5-HT3 and 5-HT4 receptors in two models of gastrointestinal transit in mice. Pascual D; Alsasua A; Goicoechea C; Martín MI Neurosci Lett; 2002 Jul; 326(3):163-6. PubMed ID: 12095647 [TBL] [Abstract][Full Text] [Related]
12. [Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy]. Okuyama K; Yoshimoto K; Iwase O; Ozeki T; Yamada Y Yakugaku Zasshi; 2008 Apr; 128(4):649-55. PubMed ID: 18379183 [TBL] [Abstract][Full Text] [Related]
13. Novel targets for the control of secretory diarrhoea. Farthing MJ Gut; 2002 May; 50 Suppl 3(Suppl 3):III15-8. PubMed ID: 11953327 [TBL] [Abstract][Full Text] [Related]
14. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Chey WD; Cash BD Expert Opin Investig Drugs; 2005 Feb; 14(2):185-93. PubMed ID: 15757394 [TBL] [Abstract][Full Text] [Related]
16. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1. Shiotani A; Kusunoki H; Ishii M; Imamura H; Manabe N; Kamada T; Hata J; Merchant JL; Haruma K Neurogastroenterol Motil; 2015 Jan; 27(1):82-91. PubMed ID: 25428414 [TBL] [Abstract][Full Text] [Related]
17. The 5-HT3 receptor as a therapeutic target. Thompson AJ; Lummis SC Expert Opin Ther Targets; 2007 Apr; 11(4):527-40. PubMed ID: 17373882 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001 [TBL] [Abstract][Full Text] [Related]